Pharmaceuticals News and Research

RSS

Marked increase in the use of herbal medicines by Australians

Australian researchers have found that the most popular herbal medicines used by Australians are aloe vera, garlic and green tea.

13 Oct 2008

OncoGenex achieves key regulatory milestone for lead product candidate

OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).

13 Oct 2008

World Bank Group President Robert B. Zoellick's remarks - Modernizing Multilateralism and Markets

Mr. Chairman, Governors, and Distinguished Guests: Thank you for joining us at these Annual Meetings. I want to express my particular thanks to our Chairman, Zoran Stavreski, and, once again, to Agustin Carstens for his leadership of the Development Committee and his partnership as a friend.

13 Oct 2008

Drug companies plan to invest in HIV/AIDS drug development, improve access, U.N. Secretary-General says

United Nations Secretary-General Ban Ki-moon on Thursday said that many large pharmaceutical companies -- including Abbott Labs, Boehringer Ingelheim, GlaxoSmithKline and Pfizer -- plan to increase their efforts to develop HIV/AIDS drugs and diagnostics for impoverished regions, Reuters reports.

13 Oct 2008

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Quark Pharmaceuticals, Inc. has announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008.

12 Oct 2008

FDA continues review of Takeda's NDA for Alogliptin

Takeda Pharmaceutical Company Limited has announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification that the U.S. Food and Drug Administration (FDA) will not be able to complete its review of the alogliptin New Drug Application (NDA) by the Prescription Drug User Fee Act (PDUFA) date of October 27, 2008.

12 Oct 2008

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

The U.S. Food and Drug Administration today approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia (BPH), a condition also known as an enlarged prostate.

12 Oct 2008

FDA licenses for marketing Cinryze for hereditary angioedema

The U.S. Food and Drug Administration today licensed for marketing the first product in the United States intended to protect people with hereditary angioedema (HAE), a rare and potentially life-threatening genetic disease. HAE affects about 6,000 to 10,000 individuals in the United States.

12 Oct 2008

Cheap 'Polypill' deals with heart disease and stroke

The 'Polypill' is a single pill which combines a range of drugs that protect against heart disease and stroke and was first considered a number of years ago as a cost effective way to significantly reduce the death toll from cardiovascular disease. But progress has been hampered by the reluctance of pharmaceutical companies to embark on a project involving inexpensive drugs which offered little financial incentive.

7 Oct 2008

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

6 Oct 2008

FDA accepts ATryn biologics license application

The US Food and Drug Administration, or FDA, has accepted for review GTC Biotherapeutics, Inc.'s Biologics License Application, or BLA, for ATryn.

6 Oct 2008

University of Minnesota task force seeks greater transparency in faculty conflicts of interest with pharmaceutical companies

A task force that examined conflicts of interest at the University of Minnesota Medical School has recommended that the university expand its disclosure policy regarding relationships between the school's faculty and the drug industry, the AP/Fargo Forum reports.

5 Oct 2008

Many receptor models used in drug design may not be useful after all

It may very well be that models used for the design of new drugs have to be regarded as impractical. This is the sobering though important conclusion of the work of two Leiden University scientists published in Science this week.

5 Oct 2008

Eli Lilly starts second global phase III trial of investigational Alzheimer's disease compound

Eli Lilly and Company today announced it will begin enrolling patients in a second Phase III study of LY450139, a gamma-secretase inhibitor being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease.

2 Oct 2008

Kill the tobacco industry, or it will keep killing

This month in Rio de Janeiro, the global tobacco industry's annual conference features a special session on what many are seeing as its Armageddon: plain, generic packaging. All packs are identical except for the brand name, printed in standard font. No colours, no logos, no box variations. Nothing but the brand and the health warning.

2 Oct 2008

Cancer Research UK and Astex Therapeutics join forces to develop new anti-cancer treatment

Cancer Research UK, Cancer Research Technology (CRT) - the charity's development and commercialisation arm - and Astex Therapeutics Limited announced today that they have agreed to take into development a potential new anti-cancer treatment.

30 Sep 2008

Multiple sclerosis patients have higher spinal fluid levels of suspicious immune molecule

A protein that helps keep immune cells quiet is more abundant in the spinal fluid of patients with multiple sclerosis (MS), further boosting suspicion that the protein, TREM-2, may be an important contributor to the disease.

29 Sep 2008

A control dashboard for the pharmaceuticals industry

Research scientists at SINTEF have developed a control dashboard for the pharmaceuticals industry. This enables all pharmacies, wholesalers and manufacturers to check where products are in the supply chain, availability, what stocks the neighbouring pharmacy has and the future prognoses.

29 Sep 2008

Concert Pharmaceuticals initiates CTP-347 phase I clinical trial

Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers.

25 Sep 2008

Discovery offers new understanding of diabetes drug target

Scientists at the University of Leicester have published findings about a new advance in the study of major diabetes drug target.

25 Sep 2008

Pharmaceuticals News and Research

Marked increase in the use of herbal medicines by Australians

OncoGenex achieves key regulatory milestone for lead product candidate

World Bank Group President Robert B. Zoellick's remarks - Modernizing Multilateralism and Markets

Drug companies plan to invest in HIV/AIDS drug development, improve access, U.N. Secretary-General says

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

FDA continues review of Takeda's NDA for Alogliptin

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

FDA licenses for marketing Cinryze for hereditary angioedema

Cheap 'Polypill' deals with heart disease and stroke

Lilly to acquire ImClone Systems for $6.5 billion

FDA accepts ATryn biologics license application

University of Minnesota task force seeks greater transparency in faculty conflicts of interest with pharmaceutical companies

Many receptor models used in drug design may not be useful after all

Eli Lilly starts second global phase III trial of investigational Alzheimer's disease compound

Kill the tobacco industry, or it will keep killing

Cancer Research UK and Astex Therapeutics join forces to develop new anti-cancer treatment

Multiple sclerosis patients have higher spinal fluid levels of suspicious immune molecule

A control dashboard for the pharmaceuticals industry

Concert Pharmaceuticals initiates CTP-347 phase I clinical trial

Discovery offers new understanding of diabetes drug target

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring